@NReguart

MD, PhD, Lead Thoracic Oncol. Unit @hospitalclinic, MedOnc, Prof. @unibarcelona, Researcher Transl Genom 🧬 Targeted Therapies @IDIBAPS, @EORTC @GECP_org, #LCSM

 Sitges, España
Joined March 2017
  • Tweets4.4K
  • Following611
  • Followers3.6K
440Media
Noemi Reguart retweeted
Stephen V Liu, MD
@StephenVLiu3h
#ESMO26 Dr. @MLJohnsonMD2 discusses ADCs in NSCLC. Notes that not all are home runs, predicting efficacy is challenging, not chemotherapy but has chemotherapy-toxicity. Much work needed to predict response, widen therapeutic window.
6
13
983
Noemi Reguart retweeted
Patrick Forde@FordePatrick5h
Now in Nature w simultaneous presentation #ESMO26 #NeoCOAST2 ! 1st platform neoadjuvant trial to associate tumor agnostic ctDNA dynamics w pCR & EFS! Privileged to be part of this effort led by Drs. Lara McGrath & Tina Cascone! Paper/slides below! 1/ #lcsm nature.com/articles/s41586-0…

ctDNA clearance and outcomes for resectable lung cancer from NeoCOAST-2

Nature - ctDNA clearance and outcomes for resectable lung cancer from NeoCOAST-2

nature.com
1
14
31
1,529
Noemi Reguart retweeted
Stephen V Liu, MD
@StephenVLiu4h
#ESMO26 Dr. @peters_solange presents phase 3 study of sigvotatug vedotin (SV, integrin beta-6 ADC) vs docetaxel in previously treated non-squamous NSCLC. No difference in survival. Some signal in driver-negative NSCLC in 2L setting (vs 3L). #ESMOAmbassadors
1
7
9
1,012
Another negative phase III trial in pretreated NSCLC! ❌ SigVie-002 sigvotatug vedotin vs docetaxel failed to meet its primary OS endpoint in non-squamous NSCLC. @peters_solange. The challenge of beating docetaxel with ADCs in 2L continues! #ESMO26 #LungCancer
7
7
543
Noemi Reguart retweeted
Stephen V Liu, MD
@StephenVLiu4h
#ESMO26 Dr. Wenfeng Fang presents update on OptiTROP-Lung04: sac-TMT (TROP2 ADC) vs platinum + pemetrexed in EGFR mutant NSCLC post TKI therapy. OS favors sac-TMT: 25.9m vs 17.4m, HR 0.69 (even better if 1L was 3G TKI). #ESMOAmbassadors
10
14
860
Just a reminder of the phase III trial landscape and outcomes reported so far with ADC-based combinations in first-line non-oncogene-addicted NSCLC.
Stephen V Liu, MD
@StephenVLiu4h
OptiTROP-Lung06 now @NEJM after #ESMO26 presentation showing Sac-TMT (TROP2 ADC) + pembro superior to standard chemotherapy + pembro. #ESMOAmbassadors @myESMO nejm.org/doi/full/10.1056/NE…

Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC | NEJM

Pembrolizumab plus chemotherapy with a platinum-based agent and pemetrexed is a widely used standard first-line treatment option for patients with programmed death ligand 1 (PD-L1)–negative advance...

nejm.org
4
11
645
Noemi Reguart retweeted
Hidehito HORINOUCHI
@HHorinouchi5h
🆙#ESMO26 Proffered Paper I: #LCSM Mets 🔥PERSEE (GFPC 01-2020): Pembrolizumab With or Without Platinum-Based Chemotherapy as First-Line Treatment in Advanced NSCLC With PD-L1 ≥50%, Phase 3 Trial 🎙️ @decroisette 🔢2614O 🎯Pembro-Chemo Improved BCR-PFS vs Pembro Alone 🎯PFS HR 0.56, mPFS 16.1 vs 6.9m 🎯OS HR 0.77 not significant; mOS 50.2 vs 29.9mo 🎯Grade≥3 TRAEs 53.8% vs 19.3% ☑️NCT04547504 🔗 cslide.ctimeetingtech.com/es… @OncoAlert @Larvol @myESMO @IASLC
Hidehito HORINOUCHI
@HHorinouchiOct 21
🆙#ESMO26 Proffered Paper I: #LCSM Mets 🔥PERSEE (GFPC 01-2020): Pembrolizumab With or Without Platinum-Based Chemotherapy as First-Line Treatment in Advanced NSCLC With PD-L1 ≥50%, Phase 3 Trial 🎙️ @decroisette 🔢2614O 🎯Pembro-Chemo Improved BCR-PFS vs Pembro Alone 🎯PFS HR 0.56, mPFS 16.1 vs 6.9m 🎯OS HR 0.77 not significant; mOS 50.2 vs 29.9mo 🎯Grade≥3 TRAEs 53.8% vs 19.3% ☑️NCT04547504 🔗 cslide.ctimeetingtech.com/es… @OncoAlert @Larvol @myESMO @IASLC
5
1
7
1,079
Noemi Reguart retweeted
Stephen V Liu, MD
@StephenVLiu5h
#ESMO26 Dr. @decroisette with the important PERSEE trial: pembrolizumab +/- chemotherapy in PDL1 high NSCLC. Enrolled 321 pts in 3y at 28 sites. Pembro-chemo PFS 16.1 vs 6.9m (HR 0.56), better across strata. OS 50.2 vs 29.9m (HR 0.77, ns) - not powered for OS. #ESMOAmbassadors
9
16
909
Impressive results Academic III PERSEE #ESMO26 @Annals_Oncology First positive random trial adding chemo to pembro in PD-L1 ≥50% NSCLC: 🔹 PFS: 16.1 vs 6.9 mo HR 0.56 🔹 OS: 50.2 vs 29.9 mo HR 0.77, NS 🔹 G≥3 TRAEs: 54% vs 19% Outstanding discussion Prof. Levy @benlevylungdoc.
10
16
574
Noemi Reguart retweeted
Helena Linardou@ElinardouHelena6h
ESMO W4O Forum is happening now- join us at Seville auditorium for a great discussion! @myESMO @peters_solange @Piuchagarrido @Women4Oncology @w4o_italy
3
11
328
Proud to be part of the Women for Oncology (W4O) session at #ESMO26 peters_solange @Piuchagarrido @ElinardouHelena highlighting barriers and opportunities for women in oncology. Inspiring call to challenge inequalities, break down barriers and empower women to thrive and lead!!!
8
25
681
Noemi Reguart retweeted
Stephen V Liu, MD
@StephenVLiuOct 24
#ESMO26 Dr. Martin Sebastian presents PACE-LUNG: phase II study of osimertinib monotherapy for EGFR NSCLC with ctDNA at 3w and if positive, add 4 cycles of chemotherapy. 72/255 were ctDNA positive at 3w. mPFS 17.8m and OS 31.5m from start of osi - no comparator but encouraging.
1
20
39
1,929
Noemi Reguart retweeted
ESMO - Eur. Oncology
@myESMO22h
A full house for Presidential Symposium I at #ESMO26.
17
1
95
4,518
Outstanding discussion by @StephenVLiu on the practice-changing DeLLphi-305 trial @sands_jacob . A new chapter in the treatment of ES-SCLC! #ESMO26. One year ago, we anticipated that we might finally be bending gravity. Today, that vision is becoming a reality!!!!!!👏👏👏👏👏
14
2
55
2,420
Impressive results from phase III DeLLphi-305 at #ESMO26 @sands_jacob: Adding tarlatamab to durvalumab maintenance in ES-SCLC 1-y OS nearly 80%!!! 🔹 OS: 21.1 vs 12.7 mo (HR 0.42) 🔹 PFS: 7.4 vs 1.9 mo (HR 0.34) A standing ovation!” 👏👏👏👏A major step forward for SCLC! @NEJM
14
1
36
1,509
Noemi Reguart retweeted
Giannis Mountzios@g_mountzios23h
#ESMO26 Presidential 1 : #SCLC DeLLphi-305: Who would have imagined some years ago that median OS of SCLC would equal that of non-AGA NSCLC! #Tarlatamab as 1L maintenance with Durvalumab after induction chemoIO in ES-SCLC improved OS from 12.7 to an impressive 21.1m, corresponding to a HR of 0.42. 80% of patients alive and 38% progression-free at 12 months The dawn of a new era for thoracic oncology and for the lives of our patients 💫✨ @myESMO @SclcSMASHERS #ESMOAmbassadors
38
2
91
4,734
Looking forward to the #ESMO26 Presidential Symposium! Exciting DeLLphi-305 data in ES-SCLC, presented by @JacobSandsMD, followed by what promises to be an insightful discussion from Dr. Stephen Liu @StephenVLiu Auditorium packed! #ESMO26
1
7
30
1,031
Noemi Reguart retweeted
ICAPEM@Icapem_vidaOct 23
🔵 ¡Enhorabuena, Dra. Pilar Garrido @Piuchagarrido ! Desde ICAPEM celebramos su reconocimiento con el @myESMO Women for Oncology Award 2026, por su impulso a la igualdad y al liderazgo de las mujeres en oncología. 👏 ¡Un orgullo para nuestra asociación! esmo.org/about-esmo/awards/e…
4
1
19
556
💜 From visibility to power, dimensions of leadership! Inspiring voices and vibrant discussion at our ESMO Women for Oncology Forum 2026 in Madrid! 👉Sunday, 25 October, 8:30-10:00 am. Seville auditorium ow.ly/xhKG50ZZXal #ESMOW4O #ESMO26 @myESMO @Women4Oncology @w4o_italy
ESMO - Eur. Oncology
@myESMOOct 22
The #ESMOW4O Forum at #ESMO26 will bring together diverse perspectives to discuss designing the next generation of #OncologyLeadership and the priorities that will shape its future. #Women4Oncology 🔗 ow.ly/3RZc50ZZX9Y
3
5
19
847
Noemi Reguart retweeted
Stephen V Liu, MD
@StephenVLiuOct 21
Join us at #ESMO26 for the "Advancing the Frontiers of Lung Cancer Care" symposium, where I will discuss KRAS, SCLC, immunotherapy, and ADCs with Dr. @FSkoulidis, Dr. Margarita Majem, and @TerriConneran. Monday, October 26, 13:00 CET, Oviedo Auditorium, Hall 5, IFEMA Madrid!
15
37
2,304
Load more